TRex Bio, Inc. (TRXB)
NASDAQ
Closed
Oct 20, 2026
Day's Range
14.2252 wk Range
13.21Overview - TRXB - TRex Bio, Inc.
Key Statistics
Valuation
Enterprise Value
182.60M
EV / EBITDA
‪-3.69‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Ownership
Shares Outstanding
27.44M
Float
3.17M
Held by Insiders
‪1.73%‬
Held by Institutions
‪0.00%‬
Price stats
50-Day Avg
‪13.88‬
200-Day Avg
‪13.88‬
Market Cap - TRXB - TRex Bio, Inc.
Peers - TRXB - TRex Bio, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- TRXBNASDAQTRex Bio, Inc.384.51MMarket Cap+0.07%52-week change—P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE51.51BMarket Cap-3.70%52-week change31.22P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.02BMarket Cap-111.89%52-week change39.09P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share22.03BMarket Cap-23.08%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S14.82BMarket Cap+8.90%52-week change17.26P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.97BMarket Cap+15.27%52-week change-17.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.10.72BMarket Cap+5.31%52-week change148.09P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - TRXB - TRex Bio, Inc.
About
TRex Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing immunoregulatory medicines for autoimmune and inflammatory diseases. The company’s work centers on tissue Treg biology, with a primary goal of restoring immune balance and supporting tissue repair through targeted therapies. Its current…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
